- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00900224
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at tissue and blood samples from patients with acute myeloid leukemia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Prospectively obtain specimens required for diagnostic review and molecular characterization ensuring eligibility for CALGB Leukemia Committee Clinical trials (for clinical trials designed to enroll specific molecular subtypes, results to determine eligibility will be reported to treating physicians no more than 72 hours after specimen receipt at the repository).
- Determine the frequency of specific gene markers (i.e., FLT3 ITD, CBF, MLL PTD, NPM1, KIT, RAS, CEBPA, WT1, JAK2, RUNX1, TET2, CBL, IDH1 and IDH2, ASXL1, mutations, aberrant BAALC, ERG, FLT3, MN1, EVI1, and APP) over-expression and levels of promoter methylation of specific genes (e.g., ESR1, WIT1, P15, MYOD1, ID4, DPK) in defined cytogenetic subgroups of patients with acute myeloid leukemia (AML).
- Correlate these gene markers with clinical and laboratory parameters in these patients.
- Correlate these gene markers with clinical outcome (i.e., complete remission [CR], disease-free survival [DFS], cumulative incidence of relapse [CIR], and overall survival [OS]) in these patients.
- Identify specific microarray multi-gene expression signatures in these patients.
- Correlate specific microarray multi-gene expression signatures with clinical and laboratory parameters in these patients.
- Correlate specific microarray multi-gene expression signatures with clinical outcome (i.e., CR, DFS, CIR, and OS) in these patients.
- Identify specific microarray multi-microRNA (miR) expression signatures in these patients
- Correlate specific microarray multi-miR expression signatures with clinical and laboratory parameters in these patients.
- Correlate specific microarray multi-miR expression signatures with clinical outcome (i.e., CR, DFS, CIR, and OS) in these patients.
- Explore the relative contribution of prognostic gene markers (i.e., FLT3 ITD, MLL PTD, NPM1, KIT, RAS, CEBPA, WT1, and JAK2 mutations, and aberrant BAALC, ERG, FLT3, MN1, and EVI1 over-expression), levels of promoter methylation of specific genes (e.g., ESR1, WIT1, P15, MYOD1, ID4, DPK), and microarray gene and miR expression signatures in defined cytogenetic subgroups of AML.
- Determine changes in these molecular markers and microarray gene and miR expression signatures at CR and relapse and the influence that these changes have on subsequent clinical course.
- Correlate the relative level of nuclear pSTAT5 and pERK in bone marrow blasts with outcome (EFS, CR, DFS, OS).
OUTLINE: This is a multicenter study.
Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, and CBL mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Mountain View, California, United States, 94040
- Camino Medical Group - Treatment Center
-
-
Delaware
-
Lewes, Delaware, United States, 19958
- Tunnell Cancer Center at Beebe Medical Center
-
Newark, Delaware, United States, 19713
- CCOP - Christiana Care Health Services
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
-
-
Florida
-
Orlando, Florida, United States, 32803-1273
- Florida Hospital Cancer Institute at Florida Hospital Orlando
-
-
Illinois
-
Bloomington, Illinois, United States, 61701
- Illinois CancerCare - Bloomington
-
Bloomington, Illinois, United States, 61701
- St. Joseph Medical Center
-
Canton, Illinois, United States, 61520
- Illinois CancerCare - Canton
-
Carthage, Illinois, United States, 62321
- Illinois CancerCare - Carthage
-
Chicago, Illinois, United States, 60637-1470
- University of Chicago Cancer Research Center
-
Chicago, Illinois, United States, 60612-7243
- University of Illinois Cancer Center
-
Eureka, Illinois, United States, 61530
- Illinois CancerCare - Eureka
-
Eureka, Illinois, United States, 61530
- Eureka Community Hospital
-
Evanston, Illinois, United States, 60201-1781
- Evanston Hospital
-
Galesburg, Illinois, United States, 61401
- Galesburg Clinic, PC
-
Havana, Illinois, United States, 62644
- Illinois CancerCare - Havana
-
Kewanee, Illinois, United States, 61443
- Illinois CancerCare - Kewanee Clinic
-
Macomb, Illinois, United States, 61455
- Illinois CancerCare - Macomb
-
Monmouth, Illinois, United States, 61462
- Illinois CancerCare - Monmouth
-
Monmouth, Illinois, United States, 61462
- OSF Holy Family Medical Center
-
Normal, Illinois, United States, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, United States, 61761
- Community Cancer Center
-
Normal, Illinois, United States, 61761
- Illinois CancerCare - Community Cancer Center
-
Ottawa, Illinois, United States, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, United States, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, United States, 61554
- Cancer Treatment Center at Pekin Hospital
-
Pekin, Illinois, United States, 61603
- Illinois CancerCare - Pekin
-
Peoria, Illinois, United States, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, United States, 61614
- Proctor Hospital
-
Peoria, Illinois, United States, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, United States, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, United States, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, United States, 61354
- Illinois CancerCare - Peru
-
Peru, Illinois, United States, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, United States, 61356
- Illinois CancerCare - Princeton
-
Spring Valley, Illinois, United States, 61362
- Illinois CancerCare - Spring Valley
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845
- Fort Wayne Medical Oncology and Hematology
-
-
Iowa
-
Iowa City, Iowa, United States, 52242-1002
- Holden Comprehensive Cancer Center at University of Iowa
-
-
Maine
-
Augusta, Maine, United States, 04330
- Harold Alfond Center for Cancer Care
-
Bangor, Maine, United States, 04401
- CancerCare of Maine at Eastern Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Greenebaum Cancer Center at University of Maryland Medical Center
-
Elkton, Maryland, United States, 21921
- Union Hospital of Cecil County
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Brigham and Women's Cancer Center
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
-
-
Michigan
-
Battle Creek, Michigan, United States, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, United States, 49307
- Mecosta County Medical Center
-
Grand Rapids, Michigan, United States, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, United States, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, United States, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Muskegon, Michigan, United States, 49444
- Mercy General Health Partners
-
Reed City, Michigan, United States, 49677
- Spectrum Health Reed City Hospital
-
Traverse City, Michigan, United States, 49684
- Munson Medical Center
-
-
Missouri
-
Columbia, Missouri, United States, 65203
- Ellis Fischel Cancer Center at University of Missouri - Columbia
-
Saint Louis, Missouri, United States, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756-0002
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Voorhees, New Jersey, United States, 08043
- Cancer Institute of New Jersey at Cooper - Voorhees
-
-
New York
-
Buffalo, New York, United States, 14263-0001
- Roswell Park Cancer Institute
-
Lake Success, New York, United States, 11042
- Monter Cancer Center of the North Shore-LIJ Health System
-
Manhasset, New York, United States, 11030
- CCOP - North Shore University Hospital
-
Manhasset, New York, United States, 11030
- Don Monti Comprehensive Cancer Center at North Shore University Hospital
-
New Hyde Park, New York, United States, 11040
- Long Island Jewish Medical Center
-
New York, New York, United States, 10021
- New York Weill Cornell Cancer Center at Cornell University
-
New York, New York, United States, 10029
- Mount Sinai Medical Center
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
Charlotte, North Carolina, United States, 28233-3549
- Presbyterian Cancer Center at Presbyterian Hospital
-
Goldsboro, North Carolina, United States, 27534
- Wayne Memorial Hospital, Incorporated
-
Greenville, North Carolina, United States, 27834
- Leo W. Jenkins Cancer Center at ECU Medical School
-
Hendersonville, North Carolina, United States, 28791
- Pardee Memorial Hospital
-
Kinston, North Carolina, United States, 28501
- Kinston Medical Specialists
-
Winston-Salem, North Carolina, United States, 27157-1096
- Wake Forest University Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210-1240
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224-1791
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
-
-
Vermont
-
Berlin, Vermont, United States, 05602
- Mountainview Medical
-
Burlington, Vermont, United States, 05401
- Fletcher Allen Health Care - University Health Center Campus
-
-
Virginia
-
Richmond, Virginia, United States, 23298-0037
- Virginia Commonwealth University Massey Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
DISEASE CHARACTERISTICS:
- Histologically confirmed acute myeloid leukemia (AML)
- Tissue samples from previously untreated patients with AML considered for enrollment onto ongoing and future CALGB treatment protocols
- AML tissue samples from companion Leukemia Tissue Bank protocol CALGB-9665 and the companion cytogenetic protocol CALGB-8461
- AML diagnostic bone marrow and/or blood samples from patients enrolled on CLB-9720, CLB-9621 (all cytogenetic subtypes), and CALGB-19808 (abnormal cytogenetics only)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group 1
Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, CBL, and DNMT3A mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Presence of molecular markers that fulfill eligibility criteria in diagnostic samples from AML patients considered for CALGB therapeutic protocols
Time Frame: baseline
|
baseline
|
|
Frequency of specific single-gene markers over-expression and levels of promoter methylation of specific genes
Time Frame: baseline
|
baseline
|
|
Predictive value of specific single-gene markers
Time Frame: baseline
|
baseline
|
|
Microarray multi-gene and multi-miR expression signatures
Time Frame: baseline
|
baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Clara Bloomfield, MD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
General Publications
- Walker CJ, Kohlschmidt J, Eisfeld AK, Mrozek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD. Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clin Cancer Res. 2019 Nov 1;25(21):6524-6531. doi: 10.1158/1078-0432.CCR-19-0725. Epub 2019 Aug 2.
- Mims AS, Kohlschmidt J, Borate U, Blachly JS, Orwick S, Eisfeld AK, Papaioannou D, Nicolet D, Mromicronzek K, Stein E, Bhatnagar B, Stone RM, Kolitz JE, Wang ES, Powell BL, Burd A, Levine RL, Druker BJ, Bloomfield CD, Byrd JC. A precision medicine classification for treatment of acute myeloid leukemia in older patients. J Hematol Oncol. 2021 Jun 23;14(1):96. doi: 10.1186/s13045-021-01110-5.
- Fobare S, Kohlschmidt J, Ozer HG, Mrozek K, Nicolet D, Mims AS, Garzon R, Blachly JS, Orwick S, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, Oakes CC, Eisfeld AK, Hertlein E, Byrd JC. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Adv. 2022 Mar 8;6(5):1371-1380. doi: 10.1182/bloodadvances.2021006242.
- Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Aug 5;116(5):788-92. doi: 10.1182/blood-2010-01-262543. Epub 2010 May 4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- adult acute myeloid leukemia with inv(16)(p13;q22)
- adult acute myeloid leukemia with t(15;17)(q22;q12)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- secondary acute myeloid leukemia
- untreated adult acute myeloid leukemia
- untreated childhood acute myeloid leukemia and other myeloid malignancies
Additional Relevant MeSH Terms
Other Study ID Numbers
- CALGB-20202
- CDR0000617738 (Registry Identifier: NCI Physician Reference Desk)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.